United Therapeutics buys Arena's hypertension drug ralinepag in deal worth $1.2 billionStaff Writer |
Acquisition Arena will grant United Therapeutics exclusive rights
Arena Pharmaceuticals and United Therapeutics Corporation announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).
In return, Arena will receive up to $1.2 billion, including an upfront payment of $800 million and potential milestone payments totaling up to $400 million based on the achievement of certain regulatory events. Additionally, Arena will receive low double-digit tiered royalties on annual net sales of ralinepag. ■
What to read next